# Canine Cancer Immunotherapy Network (K9CIN; U01 Clinical Trial Not Allowed)

Source: https://welltoldgrants.com/grants/rfa-ca-21-050-canine-cancer-immunotherapy-network-k9cin-u01-clinical-trial/  
Official notice: https://www.grants.gov/search-results-detail/334907

> National Institutes of Health offered grants to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on September 27, 2021.

| Field | Value |
|---|---|
| Opportunity number | RFA-CA-21-050 |
| Agency | National Institutes of Health |
| Status | Forecast |
| Deadline | September 27, 2021 |
| Award ceiling | not stated |
| Award floor | not stated |
| Expected awards | not stated |
| Total funding | not stated |
| Cost sharing | not required |
| Assistance Listings | 93.393, 93.394, 93.395 |

## Who can apply

- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

## What the grant funds

Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) will support canine clinical studies using immunotherapeutic agents and novel drug combinations together with laboratory correlative studies that seek to characterize and understand the cellular and molecular mechanisms that determine anti-tumor responses (or non-responses) in pet dogs with spontaneous tumors. The goal is to create a network of laboratories and canine clinical trial sites. The proposed clinical studies must include therapeutic modulation of the tumor microenvironment (TME) or must elicit direct immune-mediated destruction of cancer. Priority attributes include: combinations of immunotherapy/TME-modulating therapy with radiation therapy or other therapies (e.g., targeted therapies, chemotherapies or other immunotherapies); adoptive immune cell therapies such as CAR T-cell therapies or NK cell therapies; studies including longitudinal biopsy; and studies including tumor DNA sequencing and transcriptomics in pet dogs treated with immunotherapeutic agents. Within the network, awardees are expected to share therapeutic agents, specimens, and laboratory and clinical protocols in order to standardize and validate data generated. A companion funding opportunity will support a coordinating center that will aid in the development, standardization, harmonization, and conduct of the clinical and laboratory studies, as well as data management and statistical support across the funded U01 sites (see U24 award supported under companion RFA-CA-21-051).

## Questions people ask

### Is RFA-CA-21-050 still open?

No. It closed on September 27, 2021. A newer notice is forecast: RFA-CA-26-010, expected deadline January 25, 2027.

### Who can apply for Canine Cancer Immunotherapy Network (K9CIN; U01 Clinical Trial Not Allowed)?

National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.

### What is the deadline for Canine Cancer Immunotherapy Network (K9CIN; U01 Clinical Trial Not Allowed)?

Closed September 27, 2021. Applications are no longer accepted; the program's newer notices are on this page when there are any.

### Who has been funded under RFA-CA-21-050?

NIH RePORTER lists 5 projects funded under RFA-CA-21-050 in fiscal 2022 to 2026, at 5 institutions. The most were at Mayo Clinic Rochester, Purdue University, Tufts University Boston.

### Who has won Cancer Cause and Prevention Research grants before?

The largest recipients over five fiscal years were The Univeristy of Texas M.D. Anderson Cancer Center, Sloan-Kettering Institute for Cancer Research, The Trustees of Columbia University in the City of New York. The program made 2,517 awards worth $3.6 billion in that time.